Astellas sells off diabetes IP for $609M; Valeant snaps up Meda drug rights;

@FiercePharma: Icahn sues Forest for info on Solomon's woes. News | Follow @FiercePharma

> Astellas Pharma, Japan's No. 2 drugmaker, said it is selling diabetes-related patents to a fund for $609 million, which would then be invested in strategic initiatives. Report

> Canada's Valeant Pharmaceuticals acquired rights to market skin medicines Elidel and Xerese in the U.S., Canada and Mexico from Sweden's Meda for $76 million up front and up to $130 million over the next 18 months, plus longer-term royalties. Article

> Danish drugmaker Lundbeck will continue to sell a drug used in U.S. executions because pulling it off the market would be bad for some patients with severe epilepsy, its CEO said. News

> A U.S. court ordered the seizure of a pet drug made by pharmaceutical companies Cipla and Velcera, after ruling the drug violated a Sanofi unit's patent. Story

> Pfizer's Japanese subsidiary has begun commercial operations at a new established products division, through which it will more actively promote and develop its portfolio of older drugs. News

> Now that the U.S. Supreme Court has struck down a Vermont law that restricted the sale of prescribing information for marketing purposes, a similar law in Maine is now being sent back to a federal appeals court for judicial review. Report

> Merck's animal health division, formerly known as Intervet/Schering-Plough Animal Health, announced that it will begin using its new name, Merck Animal Health. News

> Canada's federal and provincial governments are now taking more than two and a half years, on average, to approve new prescription medicines, a new report says. Story

> Latvian pharmaceutical company Grindeks has opened a new API manufacturing plant that it predicts will add around €10 million to its annual turnover when operating at full capacity. Article

> Canada's Cipher Pharmaceuticals said Vertical Pharmaceuticals will exclusively market and distribute its drug to treat chronic pain in adults in the U.S. Report

> The deadline for implementation of a bar-code system on India's pharmaceutical exports is likely to be extended further. Item

> A third of patients with diabetes admit to regularly missing or not taking insulin treatment three days a month, according to a new poll. Story

Biotech News

@FierceBiotech:  Though widely endorsed, deals may not be R&D panacea. News | Follow @FierceBiotech 

@JohnCFierce: Lechleiter tells Reuters he's sticking to R&D budget. Investors thinking of R&D cuts? "kind of nuts." Item | Follow @JohnCFierce

> Novartis Venture Fund leads $36M raise for Sorbent. Story

> Astellas' patent sale gins $609M for new round of dealmaking. News 

> Third Rock launches new rare-disease biotech with $26M round. Report  

Vaccines News

> Transitioning to human models a big obstacle for DNA cancer vaccines. News

> Merck's Gerberding discusses advantages, challenges of vaccines. Report

> Type 1 diabetes vaccine flunks trial. Article

> Collaborations are key in vaccine industry. Item

Manufacturing News

> Brown prods FDA on foreign API link with drug shortages. Item

> DHL, BT team for RFID-secure supply chain. News 

> Musty odor drives another Tylenol recall. Article

> Baxter gets warned on missing field reports. Story

> Expansion-minded Almac stays on task. News

> Merck, UPS grow closer in expanded logistics deal. Report

And Finally... With a technological crystal ball--a.k.a. fMRI scans--scientists predicted future actions based on brain activity. Piece

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.